"Breakthrough in Treating Rare Bone Disease in Children"
A new drug, BLU-782, shows promise in treating fibrodysplasia ossificans progressiva (FOP), a rare disorder that turns soft tissues into bone. Following FDA approval of the first FOP treatment, palovarotene, BLU-782 has demonstrated success in mouse models and early human trials, potentially offering a safer option for children. This development brings hope for better management of FOP, which severely limits mobility and quality of life.
